Title : Novartis, Pfizer join forces on potentially lucrative fatty liver disease
link : Novartis, Pfizer join forces on potentially lucrative fatty liver disease
Novartis, Pfizer join forces on potentially lucrative fatty liver disease
Novartis, Pfizer join forces on potentially lucrative fatty liver diseaseJohn Miller, Michael Erman
ZURICH/NEW YORK (Reuters) - Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.
The Swiss and U.S. drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH.
Though hardly a household name, the progressive fatty liver disease with no approved treatments is poised to become the leading cause of liver transplants by 2020.
Thus Article Novartis, Pfizer join forces on potentially lucrative fatty liver disease
That's an article Novartis, Pfizer join forces on potentially lucrative fatty liver disease This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Novartis, Pfizer join forces on potentially lucrative fatty liver disease with the link address https://theleknews.blogspot.com/2018/10/novartis-pfizer-join-forces-on.html
0 Response to "Novartis, Pfizer join forces on potentially lucrative fatty liver disease"
Post a Comment